ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Kyntra Bio (KYNB)
Kyntra Bio stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$4.50▲ 0.00%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Kyntra Bio in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Kyntra Bio
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Kyntra Bio a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $3.84 and $5.06; in 9 out of 10, between $3.00 and $6.46. Estimated annual volatility is 79%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $25.5M
- 52-week high
- $11.39
- 52-week low
- $4.36
- Revenue (12 months)
- $4.6M
- Revenue growth (YoY)
- -78.3%
- Gross margin
- 91.4%
- Free cash flow (12 months)
- $54.1M
- Beta
- 1.06
What this means
ATLAS does not publish a fair value for KYNB right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks KYNB has traded between $4.36 and $11.39. Today it is 60.5% below that high and 3% above its low.
Its beta is 1.06: it moves roughly in line with the market.
About the company
Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs.
Want to see everything about Kyntra Bio?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Kyntra Bio do?
Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs.
What is the chance KYNB goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, KYNB ends the month between $3.84 and $5.06.
How big is Kyntra Bio and what is its P/E ratio?
Kyntra Bio's market capitalization is $25.5M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is KYNB?
ATLAS estimates annual volatility at 79%. In a typical month, half of the outcomes end between $3.84 and $5.06.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer